Investor Overview

Corporate Profile


Rocket Pharmaceuticals, Inc. is an emerging, clinical-stage biotechnology company focused on developing first-in-class gene therapy treatment options for rare, undertreated diseases. Rocket’s multi-platform development approach applies the well-established lentiviral virus, which we refer to as LVV, adeno-associated virus, which we refer to as AAV, gene therapy platforms.

Stock Information

NASDAQ | RCKT (Common Stock)

$15.00

 0.30 (2.04%)

High$15.16
Low$14.75
Volume42,792
Market Cap$651,992,657

December 18, 2018  10:25 a.m. ET

Minimum 15 minute delay, Data provided by Nasdaq

Stock chart for: RCKT.O.  Currently trading at $15.00 with a 52 week high of $25.96 and a 52 week low of $9.56.